Skip to main content
OpenTrials
Completed

NCT Number: NCT07637435

Role of Vascular Endothelial Markers in Predicting Renal Prognosis and Mortality in Patients Undergoing HD-AKI

The aim of this study was to evaluate the role of Activin A, Nostrin, and Angiopoetin-2 levels in predicting the prognosis of renal function and in-hospital and 6-month mortality in patients undergoing emergency hemodialysis treatment for acute kidney injury. The main questions it aims to answer are:

Acute renal injury is a clinical entity with very important consequences. Mortality and morbidity are high in patients requiring hemodialysis. This study aims to evaluate the predictive effects of certain biomarkers on outcomes such as short- and long-term monitoring of renal function, weaning or continuation of hemodialysis, in-hospital and 6-month mortality in these patients. In patients with an indication for emergency hemodialysis, the following levels will be measured before hemodialysis:

* Serum Activin A, * Serum Nostrin, * Serum Angiopoetin-2

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Kidney Injury Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Hemodialysis Kidney Diseases Male Urogenital Diseases Renal Insufficiency Urogenital Diseases Urologic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Mugla Sitki Kocman University

Muğla, Menteşe, 48000, Turkey (Türkiye)

About this study

In this single-center study, the investigators evaluated patients diagnosed with acute kidney injury (AKI) who underwent emergency hemodialysis. AKI has a high mortality rate and can be accompanied by many complications. Progression to chronic kidney disease is one of the most important of these complications. Identifying prognostic determinants in patients receiving hemodialysis treatment due to AKI can provide significant benefits for clinical practice. In this study, the investigators aimed to determine the prognosis in this patient group using some vascular-endothelial markers. The investigators collected serum samples before hemodialysis from AKI patients indicated for hemodialysis and measured the levels of Activin A, Nostrin, and Angiopoetin-2. The investigators aimed to evaluate the relationship between these levels and parameters such as in-hospital mortality, 6-month mortality, and weaning from hemodialysis after 6 months or hemodialysis dependence.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients 18 years and older of age requiring hemodialysis for acute kidney injury

Exclusion criteria

  • Patients under 18 years of age
  • Patients under chronic renal replacement therapy
  • Patients with a history of renal transplantation

Treatment and study plan

Serum samples before hemodialysis.

Diagnostic Test

Except from taking a venous blood sample there are no interventions.

Primary outcomes

  1. Correlation of serum nostrin, activin A, angiopoetin-2 levels and in-hospital clinical results and outcomes (mortality, weaning from HD)

    Time frame: From the day of the first hemodialysis session until in-hospital death or discharge. (maximum up to 100 days)

    Up to 3 months were sufficient for patient recruitment for the study. After patient recruitment was completed, the investigators followed the patients during their in-hospital days monitoring their need for hemodialysis and survival/death status.

Secondary outcomes

  1. All cause mortality and need for hemodialysis or weaning from hemodialysis

    Time frame: 180 days after the initiation of first hemodialysis session

    Patients who were discharged from the hospital after the initiation of hemodialysis were followed up for 180 days in terms of discontinuing or continuing hemodialysis treatment and survival/death status.

Sponsors and collaborators

Lead sponsor

Muğla Sıtkı Koçman University

Other

Registry information

Official study title

The Role of Vascular Endothelial Markers in Predicting Renal Function Prognosis and Mortality in Patients Undergoing Emergency Hemodialysis Due to Acute Kidney Injury

Acronym: VEMhemodiAKI

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Jun 9, 2026
Registry last updated
Jun 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.